An individual M&A theme involving the acquisition of JITSUBO as a subsidiary and the expansion of the CMC value chain from small-molecule to mid-molecule pharmaceuticals by bringing in process development, technology transfer, contract manufacturing and licensing capabilities for peptide active pharmaceutical ingredients using the Molecular Hiving method.